Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...

Japan's Daiichi Sankyo has agreed a deal to buy Ambit Biosciences of the US for up to $410 million, bringing a new leukaemia candidate into its pipeline. The $15-per-share cash deal - which could ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

Seattle’s claim against Daiichi Sankyo covers all of the Japanese firm’s antibody-drug conjugate (ADC) pipeline following the alliance between 2008 and 2015. Daiichi paid $4 billion to gain ...

Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, datopotamab deruxtecan is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programmes in ...

DS-8201: Daiichi Sankyo DS-8201 a proprietary antibody-drug ... Inactive candidates Download the Colorectal Cancer Pipeline Report to discover partnership opportunities and collaborate in driving ...

DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or ...

Daiichi Sankyo (OTCPK:DSKYF) stock slid 10% Friday after the Japanese drugmaker announced it had received approval in Japan for its DXd antibody-drug conjugate Datroway for the treatment of HR+ ...

Daiichi Sankyo. “We continue to make important progress with our approved and pipeline medicines with the goal of changing the standard of care across a wide range of cancers.” Innovation in ...

Daiichi Sankyo and AstraZeneca’s (AZN) biologics license application for datopotamab deruxtecan has been accepted and granted priority review in the U.S. for the treatment of adult patients with ...

Daiichi Sankyo has finalised the acquisition of intellectual ... The global ADC market is expected to grow as currently approved and pipeline ADCs become available for new indications and in ...